Thierry Alcindor, Senior Physician at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:
“In this paper, I and colleagues from Dana Farber News and Brigham and Women’s Hospital at Harvard Medical School look at patterns of response of dMMR or high-TMB sarcomas to ICI treatment.
Could germline versus somatic MMR deficiency make a difference?”
Title: Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency
Authors: Thierry Alcindor, David J Papke Jr, Vinayak Venkataraman, Michael J Wagner, Priscilla Merriam, Candace L Haddox, Andrew J Wagner, Nicole L Solimini, Ashwini Jambhekar, Suzanne George
Other articles featuring Dr. Alcindor on OncoDaily.